Key Investor Signals
Secured €500,000 from BII plus a DKK 4.7M grant
BioInnovation Institute admitted Anorit Medical to its 12-month Venture Lab in March 2026 with a €500,000 convertible loan. Innovation Fund Denmark awarded a further DKK 4.7M through Innobooster in 2026, its third award to the company.
Patent review found the invention novel and claims protectable
Anorit Medical reports that the Danish Patent and Trademark Office examined its first patent application and found the invention novel, with every claim considered protectable.
Prototype tested by more than 40 first-aid instructors
In mannequin testing at FUN 2025, 91.4% of participating instructors found the device easy to use and 97.1% felt confident using it.
Other Positive Signals
- COO Minik Nørreslet previously founded and sold an osteopathy clinic.
- The founding team brings relevant experience from Coloplast, NeoCare Nordic, and HAY.
- Laerdal Medical Business Development Director Leif Henriksen joined the advisory board.
- The company originated in the BioMedical Design Novo Nordisk Foundation Fellowship Programme.
- Selected for the Danish Tech Challenge and won Venture Cup Denmark's health category.
Team
Sotiria Athanasiadou
Co-founder and CEO
- Clinical Education Manager in Medical Affairs and Innovation at Coloplast from 2021 to 2023.
- Co-authored a peer-reviewed BMC Nursing study developing a urinary tract infection assessment tool, drawing on 3,544 papers and input from 90 European nurses.
- Holds an MSc in Pharmaceutical Sciences from the University of Copenhagen.
Minik Nørreslet
Co-founder and COO
- Founded an osteopathy clinic and sold it in 2024.
- Co-owns a physiotherapy clinic and is registered in Denmark as both an osteopath and physiotherapist.
- Holds an MSc in Osteopathy from Buckinghamshire New University.
Andreas Konradsen
Co-founder and CPO
- Led design, intellectual property, and product development for a neonatal intensive-care device at NeoCare Nordic from 2022 to 2024.
- Spent six years designing products for volume manufacture at HAY and Liewood.
- Trained as an industrial designer at the Royal Danish Academy of Architecture, Design and Conservation.
Product
Anorit Medical is developing an automatic ventilation device for use during cardiac arrest. A bystander places it over the patient's mouth and presses one button to deliver a controlled volume of air. The reusable device is designed to work alongside chest compressions and defibrillation. Only the patient-contact components are replaced after use. The company has built a functional prototype and tested it on resuscitation mannequins.
Automatic ventilation through a single button
The device controls the volume of each breath, removing the need for the bystander to perform mouth-to-mouth or operate a bag-valve mask.
Designed for the first person on the scene
Professional ventilation equipment requires training and often two responders. Anorit Medical is designing for someone working alone during the minutes before emergency services arrive.
Fits the existing resuscitation sequence
The device is designed to provide ventilation without interrupting chest compressions or defibrillator use, allowing it to fit the CPR sequence already taught in first-aid courses.
Market Overview
During cardiac arrest, circulation stops and effective breathing is lost. Brain injury can begin within minutes. Chest compressions require only hands, while ventilation typically depends on mouth-to-mouth or a bag-valve mask, which is difficult to use correctly without training.
Public-access defibrillators provide a possible route to market. Employers, municipalities, and community organisations already buy rescue equipment for workplaces and public spaces.
The American Heart Association estimates that approximately 350,000 cardiac arrests occur outside hospitals annually. Most happen at home, and around four in ten patients receive bystander CPR.
In a study of 1,976 out-of-hospital cardiac arrests, patients whose lungs inflated during at least half of compression pauses were over three times as likely to survive to hospital discharge.
Safe Life had distributed more than 500,000 defibrillators and expected sales above €250M in 2025, demonstrating institutional demand for rescue equipment and related services.
The global market is forecast to grow at 9.8% annually, with public access expected to be its fastest-growing end use.
Comparable Outcomes
ZOLL Medical
ZOLL Medical built defibrillators, patient monitors, and CPR-feedback devices for emergency responders. It provides a strategic precedent for the value of resuscitation hardware. Asahi Kasei completed the acquisition of ZOLL Medical in April 2012 for approximately $2.21B.
Physio-Control
Physio-Control supplied emergency medical services with LIFEPAK defibrillators, patient monitors, and devices that assist chest compressions. Stryker completed its $1.28B all-cash acquisition of Physio-Control in April 2016.
Adapt Pharma
Adapt Pharma developed NARCAN Nasal Spray, a nasal form of the emergency antidote to opioid overdose, designed so that a bystander with no training could give it correctly under pressure. Emergent BioSolutions acquired Adapt Pharma in October 2018 for $635M upfront.
Interested in More Startups Like Anorit Medical?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.